In response to the possible quality risks of some centrally purchased drugs, the National Medical Insurance Administration took the lead in the investigation.
On January 20, the National Medical Insurance Bureau said today (20th) that during the recent "two sessions" in Shanghai, some members of the Chinese People's Political Consultative Conference and medical experts reported that some collectively purchased drugs may have quality risks and other issues, and the National Medical Insurance Bureau attaches great importance to them. In order to effectively accept democratic supervision, widely listen to the voices of the clinical front line, give full ...